ARTELO BIOSCIENCES, INC.
ARTL · XNASCIK 1621221fmd_00D16A1MYPHCB9SRPS95CY5T54Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Aug 29, 2013 to Sep 30, 2026, 55 periods
| Line item | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Realized investment gains (losses) | – | – | – | – | – | – | – | – | 0 | 0 |
| Research and development | – | 1 | 1 | 2 | – | 4 | 4 | 6 | 6 | 5 |
| Total operating expenses | 0 | 2 | 3 | 5 | – | 9 | 10 | 10 | 10 | 11 |
| Operating income | (0) | (2) | (3) | (5) | – | (9) | (10) | (10) | (10) | (11) |
| Interest expense | 0 | – | – | – | – | – | 0 | 0 | 0 | 0 |
| Interest and investment income | – | – | – | 0 | – | 0 | 0 | 0 | – | – |
| Other non-operating income (expense) | (0) | – | 1 | 0 | – | 0 | 0 | 1 | 0 | (1) |
| Income tax expense | 0 | 0 | 0 | 0 | – | 0 | 0 | 0 | 0 | 0 |
| Net income | (0) | (2) | (2) | (5) | (7) | – | (10) | (9) | (10) | (13) |